Big holders of embattled Valeant Pharmaceuticals International (VRX) aren't backing down. On the contrary, Pershing Square Capital Management, the hedge fund firm managed by Bill Ackman, disclosed that it has been busy in recent days adding hundreds of millions of dollars of exposure to Valeant through stock and options. Show More Summary
Activist investor Bill Ackman’s hedge fund has increased its investment in Valeant Pharmaceuticals International. A regulatory filing from the fund says it may begin to play a larger role in the company’s day-to-day operations. Ackman’s Pershing Square Capital Management has increased its stake in Valeant to 9.9% from 5.7%. Show More Summary
Pershing Square's Bill Ackman is adding to his bets on Valeant Pharmaceuticals, the embattled drugmaker that's seen its shares fall 60% over the past three months amid scrutiny into its business practices and drug pricing strategies. William "Bill" Ackman, founder and chief executive officer of Pershing Square Capital Management Photographer: Chris [...]
(Reuters) - Bill Ackman's Pershing Square Capital Management raised its stake in Valeant Pharmaceuticals International Inc to 9.9 percent, making it the second largest shareholder in the company. The hedge fund firm previously held a stake of 5.7 percent in the drug maker. Show More Summary
In the infamous words of Kenny Rogers, "you gotta know when to fold 'em," but in the case of Bill Ackman and his Pershing Square Fund's massive losing position in Valeant (19.47 million shares at average cost of $183.57 against today's...Show More Summary
Bill Ackman's hedge fund, Pershing Square Capital Management, has boosted its stake in Valeant to 9.9% from 5.7%, according to a Monday SEC filing. Here is the statement from the firm: Pershing Square Capital Management, L.P., the investment manager for Pershing Square Holdings, Ltd. Show More Summary
The same guy also said he still believes in Bill Ackman, haters be damned.
Two days ago in “Billionaire Bitch Fight: Ackman Slams Munger, Buffett For Profiting Off Fat Americans” we highlighted an absurd back-and-forth exchange between Bill Ackman and Buffett’s incorrigible right-hand man Charlie Munger who...Show More Summary
Earlier this month a judge denied hedge fund billionaire Bill Ackman and Valeant Pharmaceuticals' motion to put a year-old insider trading case against them to bed. Valeant has a long list of problems: A stock price crushed in four weeks,...Show More Summary
Bill Ackman's war of words with Charlie Munger does more to raise questions about his judgement than revive the investment case for Valeant, which has now dragged Pershing Square's returns down 21.2% for 2015.
Links to the best reading in funds investing: Blackstone (BX) confirms an $820 million investment for 17% of NCR (NCR) — Mike Spector, Dana Mattioli and Chelsey Dulaney, The Wall Street Journal Bill Ackman snipes back at Marlie Munger over “deeply immoral” jab — Erik Holm, MoneyBeat Investors pulled a ton of cash from U.S. […]
But he's not NOT saying it.
2015 has been tough for Bill Ackman, as we noted previously, having extended his year-to-date losses to 21.2%. But Q3 was particularly noteworthy in its unhedged magnificence. As the following table shows, of all his positions, his only positive contributors to returns added a whopping 0.1%, not so much his other 13 positions... Show More Summary
Today is not that day.
It was last April when Valeant first revealed of the collusive scheme it had hatched with financier Bill Ackman: upon consultation with Ackman, Valeant's soon to be embattled CEO Michael Pearson would announce a hostile takeover bidShow More Summary
One week ago, an unexpected critic of Valeant (and by implication Bill Ackman's investment acumen) emerged when none other than Buffett's partner Charlie Munger slammed the battered pharma calling its practice of acquiring rights toShow More Summary
Activist investor Bill Ackman threw some serious shade at Charlie Munger a t the Berkshire Hathaway 50th Anniversary Symposium in New York after some comments the Berkshire executive made recently about Valeant Pharmaceuticals. Munger,...Show More Summary
Hedge fund titan Bill Ackman just turned a Warren Buffett investing maxim on its head. "Be fearful when others are fearful," Ackman said on Wednesday at the Berkshire Hathaway 50th Anniversary Symposium at the Museum of American Finance in New York. Show More Summary